China Proposes Changes for Clinical Trials Practices and Regulations

Clinical Trials Advisor
China’s Food and Drug Administration recently proposed revisions to its good clinical practices guidelines, standardizing the conduct of drug studies. According to the global law firm Ropes & Gray, the revisions are similar to those proposed by the International Conference on Harmonization guidelines.

To View This Article:


Subscribe To Clinical Trials Advisor